US8293742 — Preferential vasoconstriction compositions and methods of use
Method of Use · Assigned to Alpha Synergy Development Inc · Expires 2030-07-14 · 4y remaining
What this patent protects
This patent protects compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels using highly selective alpha-2 adrenergic receptor agonists.
USPTO Abstract
The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Drugs covered by this patent
- Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2222 |
— | Alphagan |
U-2222 |
— | Alphagan |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.